BioCardia (NASDAQ:BCDA – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.62, Zacks reports.
BioCardia Stock Down 3.0 %
Shares of NASDAQ BCDA traded down $0.08 during midday trading on Wednesday, hitting $2.55. 44,840 shares of the company’s stock were exchanged, compared to its average volume of 272,921. BioCardia has a 12 month low of $1.63 and a 12 month high of $6.41. The company’s 50 day moving average price is $2.43 and its 200 day moving average price is $2.41. The firm has a market capitalization of $11.69 million, a PE ratio of -0.61 and a beta of 1.28.
Analysts Set New Price Targets
BCDA has been the topic of several analyst reports. Alliance Global Partners raised shares of BioCardia from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 30th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of BioCardia in a report on Wednesday, December 18th.
Insider Activity at BioCardia
In related news, Director Simon H. Stertzer purchased 22,753 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were acquired at an average price of $2.30 per share, for a total transaction of $52,331.90. Following the purchase, the director now owns 40,602 shares in the company, valued at approximately $93,384.60. This represents a 127.47 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last quarter, insiders have acquired 25,353 shares of company stock worth $58,525. Company insiders own 20.00% of the company’s stock.
About BioCardia
BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
See Also
- Five stocks we like better than BioCardia
- Investing In Automotive Stocks
- Energy Transfer: Powering Data With Dividends and Diversification
- Investing in Construction Stocks
- Qualcomm Stock Is Coiling for a Breakout
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
